Drug intelligence / Profile preview

sodium phosphate dibasic heptahydrate + sodium phosphate monobasic

Development stage
Approved
Lead developer
Fresenius Kabi
Modality
Small Molecules
Administration
Intravenous, Oral
01

Overview

**sodium phosphate dibasic heptahydrate + sodium phosphate monobasic** is a parenteral phosphate replacement product used to prevent or correct hypophosphatemia, particularly in patients with restricted or absent oral intake. It is marketed as **Sodium Phosphates Injection, USP, 3 mM P/mL** and contains sodium phosphate salts that provide elemental phosphorus for addition to large-volume intravenous fluids or compounded parenteral nutrition formulations. Mechanistically, it acts as an **electrolyte and phosphate replenisher**, restoring systemic phosphate needed for intracellular energy metabolism, including ATP generation, red blood cell glucose utilization, and other phosphorylation-dependent biological processes. The product is manufactured as a generic hospital injectable by companies including Pfizer, Fresenius Kabi, and Civica.

Brand names
Sodium Phosphates Injection
Other names
sodium phosphates injectionsodium phosphate dibasic heptahydrate + sodium phosphate monobasicmonobasic sodium phosphate monohydrate + dibasic sodium phosphate anhydroussodium phosphatesphosphorus replacement
02

Targets

CA4 (Carbonic anhydrase 4)NaPi (Sodium-dependent phosphate cotransporters)

Beyond the preview

Go deeper on sodium phosphate dibasic heptahydrate + sodium phosphate monobasic.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on sodium phosphate dibasic heptahydrate + sodium phosphate monobasic.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call